NZ575920A - Pro-oxidant anti-cancer compounds - Google Patents
Pro-oxidant anti-cancer compoundsInfo
- Publication number
- NZ575920A NZ575920A NZ575920A NZ57592007A NZ575920A NZ 575920 A NZ575920 A NZ 575920A NZ 575920 A NZ575920 A NZ 575920A NZ 57592007 A NZ57592007 A NZ 57592007A NZ 575920 A NZ575920 A NZ 575920A
- Authority
- NZ
- New Zealand
- Prior art keywords
- death
- cancerous
- cell
- cancerous cell
- pro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000003244 pro-oxidative effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 230000034994 death Effects 0.000 abstract 3
- 150000005829 chemical entities Chemical class 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000003470 mitochondria Anatomy 0.000 abstract 2
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 2
- 230000004611 cancer cell death Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 231100000405 induce cancer Toxicity 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006905109A AU2006905109A0 (en) | 2006-09-15 | Pro-oxidant Anti-cancer Compounds | |
| PCT/AU2007/001371 WO2008031171A1 (en) | 2006-09-15 | 2007-09-17 | Pro-oxidant anti-cancer compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ575920A true NZ575920A (en) | 2012-08-31 |
Family
ID=39183283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ575920A NZ575920A (en) | 2006-09-15 | 2007-09-17 | Pro-oxidant anti-cancer compounds |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8410056B2 (enExample) |
| EP (1) | EP2063884B1 (enExample) |
| JP (1) | JP5396274B2 (enExample) |
| KR (1) | KR101482803B1 (enExample) |
| AU (1) | AU2007295877B2 (enExample) |
| CA (1) | CA2663474C (enExample) |
| NZ (1) | NZ575920A (enExample) |
| WO (1) | WO2008031171A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8598145B2 (en) | 2008-03-14 | 2013-12-03 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
| US8461362B2 (en) * | 2009-04-13 | 2013-06-11 | The Ohio State University Research Foundation | Protein phosphatase 2A-activating agents |
| KR20120100706A (ko) | 2009-05-20 | 2012-09-12 | 유니베르시떼 드 제네브 | 암 개시세포의 미토콘드리아 활성 저해제 및 이의 용도 |
| PT3122757T (pt) * | 2014-02-28 | 2023-11-03 | Hangzhou Dac Biotech Co Ltd | Ligantes carregados e as suas utilizações em conjugação |
| US11007182B2 (en) | 2015-04-09 | 2021-05-18 | Health Research, Inc. | Use of atpenin to activate innate immunity |
| KR102644587B1 (ko) * | 2015-12-24 | 2024-03-07 | (주)아모레퍼시픽 | 유사 세라마이드 화합물 및 그 제조방법 |
| WO2018148550A1 (en) * | 2017-02-10 | 2018-08-16 | Health Research, Inc. | Targeting mitochondrial complex ii to reduce effects of chronic hypoxia |
| WO2020051231A1 (en) * | 2018-09-04 | 2020-03-12 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Use of delta-tocotrienol for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2220541A1 (en) * | 1997-11-07 | 1999-05-07 | Mcgill University | Analogs of vitamin e |
| RU2191903C2 (ru) | 1998-07-21 | 2002-10-27 | Карпенко Анатолий Григорьевич | Глушитель шума выхлопа двигателя внутреннего сгорания |
| CA2343893C (en) | 1998-09-15 | 2008-12-30 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes |
| EP1169033A2 (en) * | 1999-04-02 | 2002-01-09 | Washington State University Research Foundation | Enhanced tissue and subcellular delivery of vitamin e compounds |
| JP4334472B2 (ja) * | 2002-06-10 | 2009-09-30 | 学校法人北里研究所 | 電子伝達系の複合体ｉｉ阻害剤 |
| US20040175415A1 (en) * | 2003-03-05 | 2004-09-09 | Chan Alvin C. | Formulations and methods of delivery of intact tocopheryl succinate to humans |
| US6716873B1 (en) * | 2003-03-20 | 2004-04-06 | Yasoo Health Inc. | Tocopherol ester compounds |
| RU2007107359A (ru) | 2004-07-28 | 2008-09-10 | ЭсДи ФАРМАСЬЮТИКАЛЗ, ИНК. (US) | Стабильная инъецируемая композиция альфа-токоферилсукцината, его аналогов и солей |
| AU2006211960A1 (en) * | 2005-02-08 | 2006-08-17 | Board Of Regents, The University Of Texas System | Compositions and methods involving MDA-7 for the treatment of cancer |
-
2007
- 2007-09-17 CA CA2663474A patent/CA2663474C/en active Active
- 2007-09-17 NZ NZ575920A patent/NZ575920A/xx unknown
- 2007-09-17 KR KR1020097007629A patent/KR101482803B1/ko not_active Expired - Fee Related
- 2007-09-17 EP EP07800325.8A patent/EP2063884B1/en active Active
- 2007-09-17 JP JP2009527656A patent/JP5396274B2/ja not_active Expired - Fee Related
- 2007-09-17 US US12/441,487 patent/US8410056B2/en not_active Expired - Fee Related
- 2007-09-17 AU AU2007295877A patent/AU2007295877B2/en active Active
- 2007-09-17 WO PCT/AU2007/001371 patent/WO2008031171A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2663474C (en) | 2017-06-27 |
| EP2063884B1 (en) | 2014-08-13 |
| KR20090089845A (ko) | 2009-08-24 |
| EP2063884A1 (en) | 2009-06-03 |
| JP5396274B2 (ja) | 2014-01-22 |
| CA2663474A1 (en) | 2008-03-20 |
| US20110059898A1 (en) | 2011-03-10 |
| WO2008031171A1 (en) | 2008-03-20 |
| US8410056B2 (en) | 2013-04-02 |
| KR101482803B1 (ko) | 2015-01-15 |
| AU2007295877A1 (en) | 2008-03-20 |
| JP2010508242A (ja) | 2010-03-18 |
| AU2007295877B2 (en) | 2013-04-18 |
| EP2063884A4 (en) | 2010-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ575920A (en) | Pro-oxidant anti-cancer compounds | |
| WO2003102215A3 (en) | Methods of identifying and isolating stem cells and cancer stem cells | |
| Li et al. | A dinuclear iridium (III) complex as a visual specific phosphorescent probe for endogenous sulphite and bisulphite in living cells | |
| EP1492440A4 (en) | NEW PROCEDURE FOR THE DIAGNOSIS AND FORECAST OF MALIGNES DISEASES | |
| BRPI0906435B8 (pt) | Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado | |
| ES2583010T3 (es) | Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer | |
| Cui et al. | A highly sensitive and selective fluorescent probe for H2S detection with large fluorescence enhancement | |
| EP3955004A3 (en) | Use of fatty acids in methods for detecting cancer | |
| WO2009114185A3 (en) | Methods and compositions for translational profiling and molecular phenotyping | |
| AR080742A1 (es) | Peptido gamma-zeina vegetal para la administracion de biomoleculas en celulas vegetales | |
| UA116618C2 (uk) | СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b | |
| WO2010030365A3 (en) | Thyroid tumors identified | |
| GB2427468A (en) | Devices and methods for enrichment and alteration of circulating tumour cells and other particles | |
| SG170065A1 (en) | Human embryonic stem cell methods and podxl expression | |
| MY145058A (en) | Prlr-specific antibody and uses thereof | |
| EP4250336A3 (en) | Methods for detecting estradiol by mass spectrometry | |
| WO2011112845A3 (en) | Methods and compositions related to a multi-methylation assay to predict patient outcome | |
| Valentine et al. | Hydrogen isotope fractionation during H2/CO2 acetogenesis: hydrogen utilization efficiency and the origin of lipid‐bound hydrogen | |
| GB2456949A (en) | Process for preparation of alkoxysilanes | |
| Zosso et al. | Whole soil warming decreases abundance and modifies community structure of microorganisms in subsoil but not in surface soil | |
| MX2010002934A (es) | Ed-b de la fibronectina como marcador de estratificacion para drogas antitumorales. | |
| MX2009001341A (es) | Anticuerpos especificos de ephb3 y usos de los mismos. | |
| WO2011074802A3 (ko) | 전립선암 진단용 키트 및 진단방법 | |
| EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
| BR112013001642A8 (pt) | coacoplamento para controlar a reatividade de reagentes em imunoensaios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: STEPHEN JOHN RALPH, AU Free format text: OLD OWNER(S): GRIFFITH UNIVERSITY Owner name: JIRI NEUZIL, NZ Free format text: OLD OWNER(S): GRIFFITH UNIVERSITY |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2014 BY CULLENS Effective date: 20130410 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2017 BY CULLENS Effective date: 20140912 |
|
| ASS | Change of ownership |
Owner name: CANCURE LIMITED, AU Effective date: 20160728 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2018 BY CULLENS PTY LTD Effective date: 20170623 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2019 BY CULLENS PTY LTD Effective date: 20180705 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2020 BY STEFFEN SCHWARZ Effective date: 20190906 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2021 BY DR. STEFFEN SCHWARZ Effective date: 20200828 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2022 BY BIRGIT KNAACK Effective date: 20210820 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2023 BY PAVIS PAYMENT GMBH Effective date: 20220906 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2024 BY BIRGIT KNAACK Effective date: 20230901 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 SEP 2025 BY BIRGIT KNAACK Effective date: 20240910 |